Zai Lab Limited (ZLAB)

34.22 +1.07 (+3.23%) At close: 04:00PM EDT

Zai Lab Limited

Jinchuang Plaza
Building 1, Fourth Floor 4560 Jinke Road Pudong
Shanghai 201210
China
86 21 6163 2588
https://www.zailaboratory.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,951

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Ying Du Ph.D.	Founder, Chairperson & CEO	1.38M	31.84M	1966
Mr. Ki Chul Cho	Chief Financial Officer	624.96k	1.55M	1978
Mr. Frazor Titus Edmondson III	Chief Legal Officer & Corp. Sec.	707.3k	N/A	1966
Dr. Alan Bart Sandler M.D.	Pres & Head of Global Devel. in Oncology	545k	N/A	1957
Ms. Ann Beasley	Chief Compliance Officer	N/A	N/A	N/A
Dr. Ning Xu M.D.	Exec. VP & Head of Clinical Operations	N/A	N/A	1965
Dr. Jonathan J. Wang M.B.A., MBA, Ph.D.	Exec. VP & Head of Bus. Devel.	N/A	N/A	1982
Dr. James Yan DABT, M.D., Ph.D.	Chief Operating Officer of R&D	N/A	N/A	1964
Dr. Harald Reinhart M.D.	Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases	N/A	N/A	1952
Mr. Yi Liang M.B.A., M.D.	Chief Commercial Officer & Pres of Greater China	N/A	N/A	1971

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.

Corporate Governance

Zai Lab Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.